Skip to main content

ibandronate

Generic: IBANDRONATE SODIUM·Brand: BONIVA, IBANDRONATE SODIUM

ibandronate: developed by 2 companies · 2 FDA decisions.

ibandronate evidence translation

What we can confirm

2 FDA records

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ibandronate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (2)
CompanyPhase
DR REDDYS LABORATORIES LTD (RDY)Approved
Teva Pharmaceutical Industries Limited (TEVA)Approved
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. (1.1) Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.2). 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women.(RDY)FDA ↗
ANDA078997OralTablet
Tentative Approval1 INDICATIONS AND USAGE Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. ( 1.1 ). Limitations of Use The optimal duration of use has not been determined. For patients at low -risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.2 ). 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal (TEVA)FDA ↗
ANDA079194OtherInjectable

Frequently asked questions

Who is developing ibandronate?

ibandronate is being developed by DR REDDYS LABORATORIES LTD, Teva Pharmaceutical Industries Limited.

What is ibandronate's latest FDA decision?

The most recent tracked FDA decision for ibandronate is Approval for 1 INDICATIONS AND USAGE Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. (1.1) Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.2). 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women., dated April 30, 2012.